Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Revenue (2016 - 2025)

Regenxbio (RGNX) has 12 years of Revenue data on record, last reported at $30.3 million in Q4 2025.

  • For Q4 2025, Revenue rose 43.0% year-over-year to $30.3 million; the TTM value through Dec 2025 reached $170.4 million, up 104.54%, while the annual FY2025 figure was $170.4 million, 104.54% up from the prior year.
  • Revenue reached $30.3 million in Q4 2025 per RGNX's latest filing, up from $29.7 million in the prior quarter.
  • Across five years, Revenue topped out at $398.7 million in Q4 2021 and bottomed at $15.6 million in Q1 2024.
  • Average Revenue over 5 years is $46.4 million, with a median of $23.2 million recorded in 2024.
  • Peak YoY movement for Revenue: skyrocketed 1758.96% in 2021, then plummeted 92.14% in 2022.
  • A 5-year view of Revenue shows it stood at $398.7 million in 2021, then tumbled by 92.14% to $31.3 million in 2022, then dropped by 29.13% to $22.2 million in 2023, then decreased by 4.5% to $21.2 million in 2024, then surged by 43.0% to $30.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $30.3 million in Q4 2025, $29.7 million in Q3 2025, and $21.4 million in Q2 2025.